epirubicin has been researched along with Carcinoma, Ductal, Breast in 156 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (8.97) | 18.2507 |
| 2000's | 60 (38.46) | 29.6817 |
| 2010's | 78 (50.00) | 24.3611 |
| 2020's | 4 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Broeks, A; Cimino-Mathews, A; Daletzakis, A; de Boo, L; Hooijberg, E; Horlings, HM; Kok, M; Linn, S; Loncova, Z; Lubeck, Y; Opdam, M; Rieder, D; Sanders, J; Sobral-Leite, M; Trajanoski, Z; van de Vijver, K; van der Wiel, R; van Rossum, A; van Tinteren, H; Vollebergh, M | 1 |
| Fujisawa, T; Higaki, K; Ishiguro, H; Kadoya, T; Kaneko, K; Masuda, N; Matsunami, N; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Sato, N; Takahashi, M; Takano, T; Tanaka-Mizuno, S; Toi, M; Yamamoto, Y; Yanagita, Y | 1 |
| Fan, Z; He, Y; Li, J; Li, Y; Ouyang, T; Wang, L; Wang, T; Xie, Y | 1 |
| Antognelli, C; Crinò, L; Eliana, R; Floriani, I; Foglietta, J; Gori, S; Ludovini, V; Minenza, E; Nocentini, G; Piattoni, S; Pistola, L; Rulli, A; Sidoni, A; Talesa, VN; Tofanetti, FR; Tonato, M | 1 |
| Hazama, Y; Ishida, T; Kurebayashi, J; Matsumoto, K; Matsumoto, R; Moriya, T; Murata, S; Murata, T; Nakai, Y; Nakamura, T; Nomura, T; Shimoya, K; Sugawara, S; Sugihara, M | 1 |
| Banke, A; Cold, S; Dahl, JS; Ewertz, M; Fosbøl, EL; Gislason, GH; Jensen, MB; Møller, JE; Poulsen, MK; Schou, M; Videbæk, L | 1 |
| Huang, L; Meng, L; Xu, Y; Zhang, W | 1 |
| Jiang, Y; Peng, Q; Tang, Z; Zhou, Q | 1 |
| Chen, J; Huan, Y; Li, D; Wang, J; Wang, L; Wang, T; Yao, Q; Yu, M; Zhang, J; Zhou, X | 1 |
| Azama, T; Kobayashi, T; Matsuda, Y | 1 |
| Chen, Q; Fan, L; Jiang, J; Qi, X; Wang, S; Yang, X; Zhang, Y | 1 |
| Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Alba, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Pascual, J; Plata-Fernández, Y; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Blohmer, JU; Eggemann, H; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hauschild, M; Huober, J; Jackisch, C; Kittel, K; Kreienberg, R; Kunz, G; Loibl, S; Nekljudova, V; Rezai, M; Schrader, I; Solbach, C; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F | 2 |
| Bauerfeind, I; Blohmer, JU; Costa, SD; Denkert, C; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Mehta, K; Paepke, S; Rezai, M; Schneeweiss, A; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Barba, G; Cicconi, L; Divona, M; Falini, B; Hasan, SK; Lo-Coco, F; Mecucci, C; Metzler, M; Ottone, T | 1 |
| Champagne, C; Gaillot-Petit, N; Guilbert, P; Lamberth, F; Looten-Vieren, L; Nguyen, TD | 1 |
| Bartsch, R; Dubsky, P; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Hartmann, BL; Hubalek, M; Jakesz, R; Lang, A; Melbinger, E; Mlineritsch, B; Muss, C; Petzer, AL; Ressler, S; Rudas, M; Singer, CF; Steger, GG; Stoeger, H; Zielinski, CC | 1 |
| Colleoni, M; Iorfida, M; Montagna, E; Peccatori, F; Petralia, G; Tomasi Cont, N | 1 |
| Ng, CH; Rozita, AM; Taib, NA; Tiong, V; Yip, CH | 1 |
| Ameye, L; Bozovic-Spasojevic, I; de Azambuja, E; Di Leo, A; Dolci, S; Larsimont, D; Loi, S; Paesmans, M; Piccart, M | 1 |
| Chan, MS; Chen, SF; Chow, LW; Felizola, SJ; Ishida, T; Nemoto, N; Ohuchi, N; Sasano, H; Tamaki, K; Wang, L | 1 |
| Babu, S; Das, U; Govind Babu, K; Jacob, L; Lakshmaiah, KC; Lokanatha, D; Suresh, TM | 1 |
| Li, J; Li, X; Liu, H; Liu, M; Wang, J; Xu, J; Yang, H; Zhang, Y | 1 |
| Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A | 1 |
| Arakawa, A; Harada-Shoji, N; Himuro, T; Hino, O; Horimoto, Y; Igari, F; Mamat, O; Saito, M; Sonoue, H; Tanabe, M; Tokuda, E; Yoshida, Y | 1 |
| Amarillo, I; Fisher, SI; Rashidi, A | 1 |
| Fu, L; Gu, F; Guo, X; Li, H; Li, S; Li, X; Liu, F; Zhai, L; Zhang, X | 1 |
| Abrial, C; Bensussan, A; Curé, H; de Boissieu, P; Garbar, C; Kwiatkowski, F; Mombelli, S; Wang-Lopez, Q | 1 |
| Chavez-MacGregor, M; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Lei, X; Mittendorf, EA; Parinyanitikul, N; Valero, V; Zhang, H | 1 |
| Kagara, N; Kim, SJ; Maruyama, N; Michishita, S; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Shimomura, A; Sota, Y | 1 |
| Boukovinas, I; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Malamos, N; Mavroudis, D; Papakotoulas, P; Saloustros, E; Ziras, N | 1 |
| Bachelot, T; Boher, JM; Delva, R; Dohollou, N; Eymard, JC; Fabbro, M; Ferrero, JM; Gonçalves, A; Leduc, B; Lemonnier, J; Lerebours, F; Linassier, C; Lotz, JP; Martin, AL; Mouret-Reynier, MA; Pierga, JY; Roché, H; Viens, P | 1 |
| Darb-Esfahani, S; Denkert, C; Eidtmann, H; Fasching, PA; Furlanetto, J; Hartmann, A; Huober, J; Jackisch, C; Klimowicz, A; Lederer, B; Loibl, S; Mehta, K; Pfitzner, B; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Kanada, Y; Kobayashi, H; Maruyama, T; Matsuzaki, H; Miyazaki, A; Natsume, T; Note, H; Sato, Y; Sawada, H; Senba, Y; Suzuki, K; Tanaka, H; Yoshioka, T | 1 |
| Che, S; Li, J; Ou, Y; Wang, M; Wu, B; Zhao, X; Zhou, C | 1 |
| Chen, K; Chen, Y; Gong, C; Nie, Y; Qu, S; Song, E; Su, F; Xiao, X | 1 |
| Du, J; Fan, L; Jiang, J; Liang, Q; Liu, J; Ming, J; Zhang, Y; Zhong, L | 1 |
| Capelan, M; Lote, H; Mohammed, K; Papadimitraki, E; Redana, S; Ring, A; Sharp, A | 1 |
| Kang, Y; Li, J; Ma, Y; Ren, W; Zang, L; Zhang, S | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Camara, O; de Gregorio, N; Decker, T; Fasching, PA; Fehm, TN; Friedl, TWP; Heinrich, G; Jaeger, B; Janni, W; Mahner, S; Ober, A; Pantel, K; Rack, BK; Schneeweiss, A; Schochter, F; Schramm, A; Trapp, E | 1 |
| Coleman, RE; El-Helw, LM; Hatton, MQ; Purohit, OP; Zekri, JM | 1 |
| Ardavanis, A; Basioukas, S; Orphanos, G; Rigatos, G; Skafida, S | 1 |
| Bowman, A; Coleman, RE; Dunn, JA; Earl, HM; Fernando, IN; Hiller, L; Howard, HC; Poole, CJ; Ritchie, DM; Wardley, AM | 1 |
| de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez-Ortega, E; Morales, F; Ortega-Granados, AL; Ramírez-Torosa, C; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Agarwal, R; Ashley, S; Chua, S; Johnston, S; Jones, RL; O'Brien, M; Smith, IE; Walsh, G | 1 |
| Duarte, M; García-Sancho, L; Gil-López, JM; Trébol, J | 1 |
| Jaen, P; Vano-Galvan, S | 1 |
| Boidot, R; Coudert, B; Fumoleau, P; Lizard-Nacol, S; Soubeyrand, MS; Vegran, F | 1 |
| Fu, JF; Hong, ZW; Wang, B | 1 |
| Brites, MM; Figueiredo, A; Frutuoso, C; Saleiro, S; Santiago, F | 1 |
| Fukuda, S; Hiraki, S; Kawaoka, T; Matsui, H; Nagashima, A | 1 |
| Hasegawa, N; Iimura, Y; Kaneko, H; Kawabata, M; Konishi, K; Shoji, Y | 1 |
| Li, T; Liu, YH; Qin, XQ; Wang, YH; Ye, JM; Yin, HF; Zhang, H | 1 |
| Accorsi, P; Candeloro, G; Necozione, S; Rea, S; Recchia, CO; Recchia, F; Tombolini, V | 1 |
| Domoto, K; Fujibayashi, M; Hirano, A; Kamimura, M; Kim, N; Kimura, K; Kinoshita, J; Ogawa, K; Shimizu, T; Watanabe, O | 1 |
| Aoki, T; Longui, CA; Melo, MB; Oliveira, AL; Rocha, MN; Rodrigues, FF; Santos, RE | 1 |
| Dufour, P; Fricker, JP; Ghnassia, JP; Petit, T; Rodier, JF; Velten, M; Wilt, M | 1 |
| Allmaier, G; Bachleitner-Hofmann, T; Bartsch, R; Baumann, S; Bergmann, M; Burghuber, C; Gnant, M; Graf, A; Greil, R; Marchetti-Deschmann, M; Michlmayr, A; Oehler, R; Pluschnig, U; Rech-Weichselbraun, I; Steger, G | 1 |
| Breugelmans, M; De Greve, J; Foulon, W; Keymolen, K; Laubach, M; Leyder, M | 1 |
| Hirakawa, K; Ishikawa, T; Kashiwagi, S; Kato, Y; Kawajiri, H; Nakata, B; Noda, S; Onoda, N; Takashima, T | 1 |
| Balslev, E; Bernsdorf, M; Ejlertsen, B; Ingvar, C; Jakobsen, EH; Jörgensen, L; Kimper-Karl, ML; Kroman, N; Saetersdal, A; Tuxen, MK | 1 |
| Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C | 1 |
| Kajiura, Y; Yagata, H; Yamauchi, H | 1 |
| Bando, H; Iwata, H; Kashiwaba, M; Mizuno, T; Murakami, S; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Yamamoto, Y | 1 |
| Baak, JP; Gilje, B; Janssen, EA; Nordgård, O; Smaaland, R; Søiland, H; Tjensvoll, K | 1 |
| Arnold, I; Shipman, KE | 1 |
| Clemens, MR; Darb-Esfahani, S; Denkert, C; Diebold, K; Dietrich, K; Eidtmann, H; Hanusch, C; Henschen, S; Hoffmann, G; Holms, F; Huober, J; Just, M; Loibl, S; Schrader, I; Solbach, C; Tesch, H; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Cortesi, E; Frati, L; Gandini, O; Gazzaniga, P; Gradilone, A; Naso, G; Nicolazzo, C; Palazzo, A; Petracca, A; Raimondi, C | 1 |
| Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A | 1 |
| Beck, T; Camara, O; du Bois, A; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Höss, C; Kahlert, S; Konecny, GE; Kreienberg, R; Kühn, T; Lebeau, A; Loibl, S; Mehta, KM; Müller, V; Stickeler, E; Untch, M; von Minckwitz, G | 1 |
| Akazawa, K; Ishihara, H; Kim, SJ; Matsushima, T; Nakayama, S; Noguchi, S; Shibayama, M; Shimazu, K; Tamaki, Y; Torikoshi, Y; Tsukamoto, F | 1 |
| Chen, SF; Gong, C; Luo, M; Su, FX; Yao, HR; Zeng, YJ | 1 |
| Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I | 1 |
| Chen, CM; Chen, S; Shao, ZM; Yang, WT; Yu, KD | 1 |
| Cui, SD; Li, LF; Li, WL; Liu, H; Liu, ZZ; Lu, ZD; Yang, H; Zhang, HW | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Breidenbach, M; Duda, V; Eichler, C; Gossmann, A; Harbeck, N; Hoopmann, M; Kates, RE; Ohlinger, R; Thomas, A; Warm, M | 1 |
| Chen, S; Fu, R; Gu, H; Li, Q; Wang, Y; Wu, H; Yuan, K; Zhang, K; Zhang, L | 1 |
| Fu, J; Leng, H; Liang, L; Liu, YL; Xing, W; Zhang, HW | 1 |
| Guli, KZ; Guo, L; Hu, X; Li, X; Li, Y; Liu, W; Ma, Y; Wen, SJ; Yang, SE; Zhao, B | 1 |
| Chen, CM; Chen, S; Shao, ZM; Yu, KD; Zhou, RJ | 1 |
| Crespo-Torres, S; Gonzalez-Perez, LM; Infante-Cossio, P; Sanchez-Gallego, F | 1 |
| Bleuse, JP; Chapelle, A; Jacot, W; Lamy, PJ; Pouderoux, S; Romieu, G; Thezenas, S | 1 |
| Chen, J; Chen, YJ; Li, HJ; Lv, Q; Tian, CX; Wang, XD; Yang, Q | 1 |
| Beckmann, MW; Dimmler, A; Fasching, PA; Haeberle, L; Hartmann, A; Koscheck, T; Lux, MP; Rauh, C; Renner, SP; Schrauder, MG; Schulz-Wendtland, R; Wachter, DL | 1 |
| Fan, Y; Li, Q; Ma, F; Wang, JY; Wang, WM; Xu, BH; Yuan, P; Zhang, P | 1 |
| Cao, X; Xue, J; Zhao, B | 1 |
| Blot, E; Bonneterre, J; Desauw, C; Fournier, C; Hornez, L; Kramar, A; Peyrat, JP; Révillion, F | 1 |
| Fersching, DM; Holdenrieder, S; Lehner, J; Nagel, D; Stötzer, OJ | 1 |
| Alba-Conejo, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Llácer, C; Lomas-Garrido, M; Navarro-Perez, V; Plata-Fernández, YM; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Carrara, HH; Silva, LM; Takahashi, CS | 1 |
| Ahern, R; Archer, C; Dowsett, M; Krajewska, M; Krajewski, S; Naito, M; Parton, M; Reed, J; Smith, I | 1 |
| Inaji, H; Kasugai, T; Koizumi, M; Komoike, Y; Koyama, H; Motomura, K; Nose, T; Sawai, Y | 1 |
| Abali, H; Celik, I | 1 |
| Brinkbäumer, K; Hahn, K; Kessler, M; Linke, R; Sommer, H; Tiling, R; Untch, M | 1 |
| Buch, RS; Reichert, TE; Schmidt, M | 1 |
| Buksmaui, S; Hausmaninger, H; Heinrich, B; Höffken, K; Krejcy, K; Miller, MA; Morack, G; Possinger, K; Wallwiener, D | 1 |
| He, PQ; Li, YF; Liu, GY; Shen, ZZ; Sheng, Y; Shi, JY; Su, FX; Yang, MT; Zou, Q | 1 |
| Allred, DC; Arpino, G; Ciocca, DR; Daguerre, P; Elledge, R; Gago, F; Leuzzi, M; Mohsin, SK; Vargas-Roig, L; Weiss, H | 1 |
| Annane, K; Bergerat, JP; Dufour, P; Liegeois, P; Mathelin, C | 1 |
| Hitzl, W; Peintinger, F; Prokop, E; Reitsamer, R | 1 |
| Pan, CE; Wu, WJ; Zeng, J | 2 |
| Cold, S; Düring, M; Ewertz, M; Knoop, A; Møller, S | 1 |
| Bolton-Maggs, P; Flavin, A | 1 |
| Chen, L; Jiang, WZ; Lu, YF; Pan, CE; Wu, WJ; Zeng, J | 1 |
| Bonneterre, J; Campone, M; Fargeot, P; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P | 1 |
| Bafaloukos, D; Bourli, A; Christodoulou, C; Dafni, U; Fillipidis, T; Fountzilas, G; Gogas, H; Kafiri, G; Karagianni, E; Kyriakou, V; Malamou-Mitsi, V; Markaki, S; Papadopoulos, S; Papakostas, P; Papaspyrou, I; Pavlakis, K; Scopa, C; Sotiropoulou, M; Toliou, T; Tzaida, O; Vlachodimitropoulos, D | 1 |
| Boidot, R; Bonnetain, F; Lizard-Nacol, S; Oudin, C; Riedinger, JM; Végran, F | 1 |
| Angellier, E; Berdah, JF; Buyse, M; Fabbro, M; Greget, S; Herait, P; Jehl, V; Laplaige, P; Piedbois, P; Priou, F; Serin, D; Teissier, E; Valenza, B | 1 |
| Blanc-Fournier, C; Chasle, J; Guedin, P; Lacroix, J | 1 |
| Karakuzu, A; Koc, M; Ozdemir, S | 1 |
| Hata, Y; Taguchi, K; Takahashi, H; Takahashi, M; Tamura, M; Todo, S; Watanabe, K | 1 |
| Calpena, R; Cansado Martínez, P; Lacueva Gómez, FJ; Martínez Banaclocha, N; Merck, B; Pérez Ramos, M | 1 |
| Andre, F; Broglio, K; Buzdar, AU; Cristofanilli, M; Esteva, FJ; Fritsche, H; Hall, A; Hortobagyi, GN; Mazouni, C; Pusztai, L | 1 |
| Suzuki, M | 1 |
| Ando, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T; Tamada, S; Tsuchimochi, S | 1 |
| Ames, FC; Babiera, GV; Feig, BW; Francis, A; Gilcrease, MZ; Hunt, KK; Kuerer, HM; Meric-Bernstam, F; Ross, MI; Shen, J | 1 |
| Jiang, DQ; Li, S; Long, F; Xu, H; Zhang, B; Zhang, Q; Zhao, L | 1 |
| Galid, A; Gnant, M; Greil, R; Haid, A; Jakesz, R; Klug, E; Kubista, E; Kwasny, W; Lang, A; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Singer, CF; Steger, GG; Tausch, C; Wenzel, C | 1 |
| Adjadj, DJ; Aubard, Y; Benyoub, A; Bonnier, P; Clavère, P; Genet, D; Juin, P; Labourey, JL; Lebrun-Ly, V; Lejeune, C; Martin, J; Piana, L; Tubiana-Mathieu, N; Venat-Bouvet, L | 1 |
| Akiyama, F; Horii, R; Ito, Y; Iwase, T; Matsuura, M; Miki, Y | 1 |
| Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S | 1 |
| Benítez-Bribiesca, L; Bravo, JL; Del Castillo, ER; Gallegos-Hernández, F; Ostrosky-Wegman, P; Peñarroja-Flores, R; Sánchez-Suárez, P; Toledo-García, J | 1 |
| Jin, WR; Li, LF; Liu, ZB; Shao, ZM; Shen, ZZ; Xu, XJ; Zhao, Y | 1 |
| Hamaoka, T; Hayashi, N; Kawasaki, T; Kikuchi, M; Nakamura, S; Suzuki, K; Tsugawa, K; Tsunoda-Shimizu, H; Yagata, H | 1 |
| Hao, XM; Hui, R; Zhang, J; Zhang, M | 1 |
| Arima, N; Iwase, H; Kai, K; Miyayama, H; Nishimura, R; Yamamoto, Y | 1 |
| Adrover, E; Alba, E; Almenar, S; Alvarez, I; Alvarez, JV; Antón, A; Aranda, E; Baena, JM; Calvo, L; Crespo, C; de Alava, E; García Puche, JL; Gonzalez, S; González-Palacios, JF; Gracia Marco, JM; Guitián, MD; Lluch, A; López García-Asenjo, JA; López-Vega, JM; Martín, M; Mayordomo, JI; Mel, JR; Modolell, A; Munárriz, B; Palacios, J; Pelegrí, A; Plazaola, A; Ramos, M; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Sánchez-Rovira, P; Seguí, MA; Vera, F | 1 |
| Matsuno, S; Migita, T; Saito, Y; Shibata, C; Shiiba, K | 1 |
| Bastert, G; Huober, J; Junkermann, H; Kaufmann, M; Leppien, G; Otto, HF; Schmid, H; Sinn, HP | 1 |
| Berger, C; Body, G; Bougnoux, P; Calais, G; Chapet, S; Descamps, P; Lansac, J; Le Floch, O; Reynaud-Bougnoux, A | 1 |
| Ogawa, Y; Ogoshi, S; Ohmori, Y; Okazaki, Y; Tanaka, Y; Toki, T | 1 |
| Junkermann, H; Schmid, H; Sinn, HP; Wallwiener, D | 1 |
| Camargo, EE; Coudry, R; Joaquim, AI; Ramos, CD; Sagarra, AJ; Sagarra, RA | 1 |
| Rieger, N; Stahl, J; Wattchow, D | 1 |
| Basser, RL; Beaty, AE; Busmanis, IA | 1 |
| Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M | 1 |
| Arnoud, L; Belichard, C; Coudert, B; Darut-Jouve, A; Guerrin, J; Jolimoy, G | 1 |
| Chen, Z; Li, G; Liu, F | 1 |
| Emi, Y; Kai, S; Kano, T; Nishijima, N; Rai, Y | 1 |
| Hada, M; Hagiwara, J; Kamiya, K; Koshizuka, K; Muto, S; Nakagomi, H; Tada, Y; Takano, K | 1 |
| Hirata, K; Ohmura, T; Ohshima, H; Okazaki, A; Okazaki, M; Watanabe, Y; Yamamoto, M; Yamashiro, K | 1 |
| Avril, N; Dose, J; Graeff, H; Jänicke, F; Kuhn, W; Nährig, J; Römer, W; Sattler, D; Schelling, M; Schwaiger, M; Werner, M | 1 |
| Dai, A; Feng, J; Zheng, X | 1 |
| Asselain, B; Beuzeboc, P; Diéras, V; Dorval, T; Extra, JM; Jouve, M; Laurence, V; Mouret, E; Palangié, T; Pierga, JY; Pouillart, P; Scholl, S; Vincent-Salomon, A | 1 |
| Hlawatsch, A; Hoffmann, G; Kuner, RP; Teifke, A; Thelen, M; Zamboglou, N | 1 |
| Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS | 1 |
| Kawahara, H; Sakurai, T; Tatematsu, H; Yamamoto, T; Yamataka, K | 1 |
| Hara, Y; Hikosaka, Y; Iwase, H; Kobayashi, S; Toyama, T; Yamashita, H | 1 |
| Haegele, P; Lehmann, S; Moyses, B; Petit, T; Rodier, JF; Schraub, S; Velten, M | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Rudas, M; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
2 review(s) available for epirubicin and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Receptors, Estrogen; Taxoids | 2011 |
Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Epirubicin; Female; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Recurrence, Local | 2002 |
43 trial(s) available for epirubicin and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphocytes, Tumor-Infiltrating; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Thiotepa; Triple Negative Breast Neoplasms | 2020 |
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Young Adult | 2020 |
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Endostatins; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Quality of Life; Taxoids; Young Adult | 2013 |
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Diphosphonates; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Ibandronic Acid; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult | 2013 |
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Trastuzumab | 2014 |
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Everolimus; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Sirolimus; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden; Ultrasonography; Young Adult | 2013 |
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Proportional Hazards Models; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids; Time Factors; Trastuzumab; Young Adult | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2015 |
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Prevalence; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Young Adult | 2017 |
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Heart; Heart Function Tests; Humans; Liver; Liver Function Tests; Lung; Paclitaxel; Prospective Studies; Respiratory Function Tests; Survival Rate | 2008 |
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Middle Aged; Molecular Diagnostic Techniques; Neoadjuvant Therapy; Prognosis; Receptors, Cytoplasmic and Nuclear; Remission Induction | 2008 |
A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Patient Selection; Pilot Projects; Polyethylene Glycols; Prognosis; Recombinant Proteins; Survival Rate; Treatment Outcome | 2009 |
Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome | 2009 |
Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; CD4-CD8 Ratio; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-2; Killer Cells, Natural; Methotrexate; Middle Aged; Neoplasm Staging; Prospective Studies; Treatment Outcome; Tretinoin | 2010 |
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Complement System Proteins; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Plasma; Predictive Value of Tests; Taxoids; Validation Studies as Topic | 2010 |
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Fever; Gefitinib; Humans; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neutropenia; Quinazolines; Receptors, Estrogen; Research Design; Treatment Outcome; Tumor Burden | 2011 |
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Health Status; Humans; Kaplan-Meier Estimate; Methotrexate; Paclitaxel; Prospective Studies; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Methotrexate; Middle Aged; Mitotic Index; Neoplasm Micrometastasis; Prognosis; Tamoxifen; Treatment Outcome | 2011 |
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Remission Induction; Survival Rate; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; CDC2 Protein Kinase; Cyclin-Dependent Kinase 2; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptors, Steroid; Risk Factors; Treatment Outcome | 2012 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Finland; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle-epirubicin in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Charcoal; Epirubicin; Female; Humans; Injections, Intralymphatic; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nanoparticles; Neoplasm Staging; Prognosis | 2012 |
[Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Premenopause; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vomiting | 2012 |
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2013 |
The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cholera Toxin; Cyclophosphamide; Diarrhea; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Epirubicin; Female; Fluorouracil; Ghrelin; Glucagon-Like Peptide 2; Haptoglobins; Humans; Intestinal Absorption; Intestinal Mucosa; Italy; Lactulose; Mannitol; Middle Aged; Peptides; Permeability; Prospective Studies; Protein Precursors; Stomatitis; Time Factors; Treatment Outcome | 2013 |
Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2004 |
[Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 2005 |
Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Remission Induction; Taxoids; Treatment Outcome | 2005 |
[Effect of preoperative lymphatic chemotherapy on Bcl-2 and Bax expression in axillary metastasis of breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Apoptosis; Axilla; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma, Ductal, Breast; Epirubicin; Female; Humans; Injections, Intralymphatic; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Preoperative Care; Proto-Oncogene Proteins c-bcl-2 | 2005 |
Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prognosis; Stereoisomerism; Survival Rate; Time Factors | 2005 |
[Impact of preoperative lymphatic chemotherapy on relapse and metastasis of breast cancer and its mechanism].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Apoptosis; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Epirubicin; Fas Ligand Protein; fas Receptor; Female; Humans; Injections, Intralymphatic; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Single-Blind Method | 2005 |
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Neoplasms, Second Primary; Postmenopause; Receptors, Estrogen; Retrospective Studies; Survival Rate; Tamoxifen | 2006 |
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gene Expression; Humans; Methotrexate; Middle Aged; Molecular Diagnostic Techniques; Paclitaxel; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Tumor Suppressor Protein p53 | 2006 |
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 rando
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Kinetics; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2007 |
[Efficacy of activated charcoal-epirubicin suspension for treatment of breast cancer with axillary metastasis].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Charcoal; Epirubicin; Female; Humans; Injections, Intralymphatic; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2006 |
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Taxoids | 2007 |
[Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Topics: Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neutropenia; Vomiting | 2007 |
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2008 |
[Influence of preoperative on gastric cancer tissues and cells].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Preoperative Care; Stomach Neoplasms | 1997 |
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Prospective Studies; Survival Rate; Taxoids | 2002 |
111 other study(ies) available for epirubicin and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2021 |
Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gene Frequency; Genetic Association Studies; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Kaplan-Meier Estimate; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies | 2017 |
[A Case Report of Surgery and Chemotherapy for a Patient with Rapidly Progressing Breast Cancer during Pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease Progression; Epirubicin; Female; Humans; Mastectomy, Radical; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic | 2018 |
Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiotoxicity; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Denmark; Docetaxel; Epirubicin; Female; Heart Failure; Humans; Incidence; Longitudinal Studies; Mastectomy, Segmental; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Risk; Stroke Volume; Trastuzumab | 2019 |
Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; China; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Incidence; Lung Diseases, Interstitial; Middle Aged; Neoplasm Invasiveness; Polyethylene Glycols; Prognosis; Retrospective Studies | 2020 |
[Velocity vector imaging assessment of early epirubicin-induced myocardial damage].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Flow Velocity; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiac Volume; Case-Control Studies; Echocardiography; Elasticity Imaging Techniques; Epirubicin; Female; Humans; Middle Aged; Ventricular Dysfunction, Left | 2013 |
[A case of a patient with breast cancer, diagnosed from sternal metastasis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Chemoradiotherapy; Cyclophosphamide; Epirubicin; Female; Humans; Mastectomy, Segmental; Neoplasm Staging; Sternum; Taxoids | 2013 |
Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor Modulators; Estrogens; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Letrozole; Male; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Progesterone; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Triazoles | 2013 |
Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Dyspepsia; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gastrins; Gastrointestinal Motility; Gastrointestinal Tract; Ghrelin; Humans; Leptin; Middle Aged; Motilin; Neoplasm Staging; Pepsinogen A; Pepsinogen C; Peptide Fragments; Prognosis; Prospective Studies; Syndrome | 2013 |
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23).
Topics: Antibiotics, Antineoplastic; Base Sequence; Breast Neoplasms; Carcinoma, Ductal, Breast; Chromosome Breakpoints; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Epirubicin; Female; Genetic Loci; Humans; Idarubicin; Leukemia, Biphenotypic, Acute; Leukemia, Promyelocytic, Acute; Middle Aged; Molecular Sequence Data; Multigene Family; Topoisomerase Inhibitors; Translocation, Genetic | 2014 |
[Potential indications for helical tomotherapy in breast cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Funnel Chest; Hodgkin Disease; Humans; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Obesity; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids | 2014 |
Whole-body magnetic resonance imaging, metastatic breast cancer and pregnancy: a case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Epirubicin; Female; Humans; Labor, Induced; Magnetic Resonance Imaging; Mastectomy, Modified Radical; Neoplasm Staging; Pregnancy; Pregnancy Complications, Neoplastic; Radiotherapy; Tamoxifen; Treatment Outcome; Whole Body Imaging | 2014 |
Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Estradiol; Female; Fluorouracil; Follicle Stimulating Hormone; Humans; Incidence; Induction Chemotherapy; Menstruation; Middle Aged; Premenopause; Primary Ovarian Insufficiency; Prospective Studies; Retrospective Studies; Tamoxifen; Taxoids; Young Adult | 2014 |
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Methotrexate; Middle Aged; Prognosis; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Forkhead Transcription Factors; Humans; Immunohistochemistry; Immunophenotyping; Lymphocyte Subsets; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Stromal Cells; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Taxoids; Tumor Microenvironment | 2014 |
The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; India; Induction Chemotherapy; Lymphatic Metastasis; Medical Records; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Postmenopause; Premenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Rural Population; Tertiary Care Centers; Treatment Outcome | 2014 |
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Epirubicin; ErbB Receptors; Female; Follow-Up Studies; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids | 2014 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Gene Knockdown Techniques; Hepatocyte Nuclear Factor 3-alpha; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2015 |
BRCA2-associated therapy-related acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Genes, BRCA2; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Taxoids | 2015 |
The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Neoadjuvant Therapy; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Confounding Factors, Epidemiologic; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; France; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Risk Factors; Taxoids; Treatment Outcome | 2015 |
Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2015 |
Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Cyclophosphamide; Decision Support Techniques; Epirubicin; Estrogen Receptor alpha; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Tumor Burden; Young Adult | 2015 |
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cell Cycle Proteins; Class I Phosphatidylinositol 3-Kinases; Cyclophosphamide; DNA Mutational Analysis; Docetaxel; Epirubicin; Gene Expression; Humans; Middle Aged; Mutation; Phosphoproteins; PTEN Phosphohydrolase; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
[A Case of Locally-Advanced Breast Cancer with Liver Metastasis, Treated with Mastectomy of the Primary Tumor after Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Estrogen Replacement Therapy; Female; Humans; Liver Neoplasms; Mastectomy; Neoplasm Staging; Tamoxifen | 2015 |
Role of the Intravoxel Incoherent Motion Diffusion Weighted Imaging in the Pre-treatment Prediction and Early Response Monitoring to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests | 2016 |
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Multivariate Analysis; Neoadjuvant Therapy; Neutrophils; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Evaluation of the tracing effect of carbon nanoparticle and carbon nanoparticle-epirubicin suspension in axillary lymph node dissection for breast cancer treatment.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Medullary; Case-Control Studies; Charcoal; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Nanoparticles; Neoplasm Invasiveness; Neoplasm Staging; Prognosis | 2016 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Incidence; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pulmonary Embolism; Retrospective Studies; Risk Factors; Sentinel Lymph Node Biopsy; Stroke; Taxoids; Thromboembolism; Venous Thrombosis | 2016 |
Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Elasticity Imaging Techniques; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden; Ultrasonography, Mammary | 2016 |
Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual function.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease-Free Survival; Epirubicin; Female; Fertility; Humans; Medical Records; Middle Aged; Retrospective Studies; Vinblastine; Vinorelbine | 2008 |
Coincidential successful treatment of Jessner-Kanof disease with chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphocytes; Mastectomy, Radical; Recurrence; Skin Diseases; Time Factors; Treatment Outcome | 2008 |
[Acute abdomen in a chemotherapy treated breast cancer patient].
Topics: Abdomen, Acute; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Taxoids | 2009 |
Images in clinical medicine. Extravasation of epirubicin.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Infusions, Intravenous; Middle Aged | 2009 |
[Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Survival Rate | 2009 |
A remarkable case of cutaneous metastatic breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Humans; Mammaplasty; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Nitriles; Radiography; Skin Neoplasms; Taxoids; Triazoles | 2009 |
[A case of giant breast cancer performed a radical excision after neoadjuvant chemotherapy].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy | 2009 |
[A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Goserelin; Humans; Mastectomy; Neoadjuvant Therapy; Premenopause; Tamoxifen | 2010 |
[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids | 2009 |
Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Trastuzumab; Treatment Outcome | 2010 |
GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brazil; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Middle Aged; Polymorphism, Genetic; Treatment Outcome | 2010 |
Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Logistic Models; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Patient Selection; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2010 |
Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Limb Deformities, Congenital; Male; Micrognathism; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First | 2011 |
[A case of multicentric breast cancer in which an effect of neoadjuvant chemotherapy had a disparity].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Multiple Primary | 2010 |
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fibrosis; Fluorouracil; Follow-Up Studies; Heart; Humans; Inflammatory Breast Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Radiation Injuries; Radiation Pneumonitis; Survival Rate; Tamoxifen; Time Factors; Vincristine | 2012 |
Case of epirubicin-induced cardiomyopathy in familial cardiomyopathy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiac Myosins; Cardiomegaly; Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Death, Sudden, Cardiac; Dothiepin; Dyspnea; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Male; Mastectomy, Segmental; Middle Aged; Migraine Disorders; Mutation, Missense; Myosin Heavy Chains; Point Mutation; Radiotherapy, Adjuvant | 2011 |
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Circulating tumor cells count and characterization in a male breast cancer patient.
Topics: Breast Neoplasms, Male; Carboplatin; Carcinoma, Ductal, Breast; Cell Count; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, erbB-2; Humans; Immunochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Poly-ADP-Ribose Binding Proteins; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Ubc9 expression predicts chemoresistance in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Proportional Hazards Models; Remission Induction; Tumor Burden; Ubiquitin-Conjugating Enzymes; Up-Regulation | 2011 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Medullary; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cathepsin D; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prognosis; Vinblastine; Vinorelbine; Young Adult | 2012 |
[Predictive value of (99)Tc(m)-MIBI scintimammography in evaluation of the efficacy of neoadjuvant chemotherapy in patients with operable breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Remission Induction; Taxoids; Technetium Tc 99m Sestamibi | 2011 |
3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Imaging, Three-Dimensional; Middle Aged; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Ultrasonography, Mammary | 2011 |
Identification of potential markers related to neoadjuvant chemotherapy sensitivity of breast cancer by SELDI-TOF MS.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Complement C3a; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Proteomics; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2012 |
[Invasive ductal carcinoma and chronic lymphocytic leukemia: a unique case of collision tumor in breast].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel | 2011 |
[Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Inhibitor of Apoptosis Proteins; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Receptor, ErbB-2; Remission Induction; RNA, Messenger; Survivin; Taxoids | 2011 |
Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vinblastine; Vinorelbine | 2012 |
Mandibular metastases as first clinical sign of an occult male breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Mandibular Condyle; Mandibular Neoplasms; Radiography | 2012 |
Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy.
Topics: Acid Phosphatase; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Breast Neoplasms; Calcium; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Collagen; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Isoenzymes; Middle Aged; Neoadjuvant Therapy; Osteoprotegerin; Peptide Fragments; Prevalence; RANK Ligand; Retrospective Studies; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Taxoids; TNF-Related Apoptosis-Inducing Ligand; Vitamin D; Vitamin D Deficiency | 2012 |
Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Logistic Models; Mastectomy; Middle Aged; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Contrast Media; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Ultrasonography, Doppler, Color; Ultrasonography, Mammary | 2012 |
Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Protein Array Analysis; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Taxoids | 2013 |
Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; DNA; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2013 |
Study of chromosome damage in patients with breast cancer treated by two antineoplastic treatments.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Division; Chromosome Aberrations; Chromosomes, Human; Cyclophosphamide; DNA Damage; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Mitotic Index; Sister Chromatid Exchange | 2002 |
Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Caspase 3; Caspase 6; Caspases; Cisplatin; Cyclophosphamide; Deoxyribonucleases; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Proteins; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; X-Linked Inhibitor of Apoptosis Protein | 2002 |
High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Central Nervous System Neoplasms; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Taxoids | 2002 |
Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography.
Topics: Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Epirubicin; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Mammography; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Radionuclide Imaging; Technetium Tc 99m Sestamibi; Treatment Outcome | 2003 |
[Acute tongue necrosis provoked by epirubicin-cyclophosphamide treatment for invasive ductal breast cancer].
Topics: Acute Disease; Airway Obstruction; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Necrosis; Tongue; Tongue Diseases | 2003 |
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, Neoplasm; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Proliferation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Epirubicin; Female; Genes, erbB-2; Humans; Middle Aged; Neoplasm Staging; Pilot Projects; Predictive Value of Tests | 2005 |
Chemotherapy for breast cancer during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prenatal Exposure Delayed Effects | 2005 |
Epirubicin for breast cancer may cause considerable venous sclerosis.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Epirubicin; Female; Humans; Middle Aged; Sclerosis; Venous Thrombosis | 2005 |
Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
Topics: Alternative Splicing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Caspase 3; Caspase Inhibitors; Caspases; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Drug Resistance, Neoplasm; Enzyme Precursors; Epirubicin; Female; Fluorouracil; Gene Expression Regulation; Humans; Middle Aged; Neoadjuvant Therapy; Tumor Cells, Cultured | 2006 |
[Breast carcinoma and bone chondrosarcoma: a new syndrome?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Chondrosarcoma; Combined Modality Therapy; Cyclophosphamide; Diagnosis, Differential; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Mammography; Middle Aged; Phenotype; Radiography, Thoracic; Radiotherapy Dosage; Ribs; Syndrome; Taxoids; Tomography, X-Ray Computed | 2006 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Fatal Outcome; Fluorouracil; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Mastectomy, Radical; Megestrol Acetate; Middle Aged; Paclitaxel; Palliative Care; Skin Neoplasms | 2006 |
[Efficacy and toxicity of combination treatment with epirubicin (EPI) plus docetaxel (DOC) in advanced breast cancer].
Topics: Adult; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Taxoids | 2006 |
Infiltrating ductal carcinoma and synchronous malignant phyllodes tumour. Diagnostic and therapeutic approaches.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Mastectomy, Modified Radical; Mastectomy, Simple; Middle Aged; Neoplasms, Multiple Primary; Phyllodes Tumor; Radiotherapy, Adjuvant; Remission Induction | 2006 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene | 2007 |
[A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Inflammation; Mammography; Middle Aged; Remission Induction; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Mammary | 2007 |
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Fine-Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Doxorubicin; Epirubicin; False Negative Reactions; Feasibility Studies; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Preoperative Care; Sentinel Lymph Node Biopsy; Time Factors; Ultrasonography, Mammary | 2007 |
[Assessment of neoadjuvant chemotherapy in breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Logistic Models; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2006 |
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose Fractionation, Radiation; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Middle Aged; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Histological features of breast cancer, highly sensitive to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2007 |
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cyclophosphamide; Diphosphonates; Eccrine Glands; Epirubicin; Fluorouracil; Humans; Ibandronic Acid; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Radiotherapy; Sweat Gland Neoplasms; Tamoxifen; Tomography, X-Ray Computed | 2007 |
DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Comet Assay; Cyclophosphamide; DNA Damage; Epirubicin; Female; Fluorouracil; Humans; Lymphocytes; Middle Aged | 2008 |
Integrated gene expression profile predicts prognosis of breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Prognosis; Proportional Hazards Models; RNA, Messenger; RNA, Neoplasm; Young Adult | 2009 |
Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Diagnostic Imaging; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Stereoisomerism; Treatment Outcome | 2008 |
Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids | 2009 |
[A case of inflammatory breast cancer treated with preoperative intra-arterial infusion chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Mastectomy, Extended Radical; Preoperative Care | 1994 |
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Division; Cell Survival; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Premedication | 1994 |
Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cobalt Radioisotopes; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy, Modified Radical; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Tamoxifen; Treatment Failure; Vindesine | 1994 |
A case of advanced male breast cancer successfully treated by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy combined with tamoxifen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Fluorouracil; Humans; Lymphatic Metastasis; Male; Tamoxifen; Thoracic Neoplasms | 1995 |
[Response evaluation with mammography and ultrasound].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Humans; Mammography; Neoplasm Staging; Treatment Outcome; Ultrasonography, Mammary | 1996 |
Tc-99m sestamibi scintimammography in the evaluation of response of breast carcinoma to chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Evaluation Studies as Topic; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy, Modified Radical; Neoplasm Staging; Premenopause; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Treatment Outcome | 1997 |
Intractable Crohn's colitis and perianal disease responding to cyclophosphamide and epirubicin.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Colitis; Crohn Disease; Cyclophosphamide; Epirubicin; Female; Humans; Immunosuppressive Agents; Mastectomy; Middle Aged; Rectal Diseases | 1997 |
Isolated pleural effusion with hematopoietic cells of mixed lineage in a patient receiving granulocyte-colony-stimulating factor after high-dose chemotherapy.
Topics: Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Cytodiagnosis; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Macrophages; Monocytes; Neoplasm Staging; Pleural Effusion; Recombinant Proteins | 1998 |
[A case of giant advanced breast cancer responding remarkably to chemo-endocrine therapy chiefly with doxifluridine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Floxuridine; Fluorouracil; Humans; Pleural Effusion, Malignant; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1998 |
[Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Thrombocytopenia | 1999 |
[A patient with hepatic metastasis of breast cancer successfully treated with combined chemoendocrine therapy using epirubicin, tegafur and tamoxifen].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Epirubicin; Female; Humans; Liver Neoplasms; Middle Aged; Remission Induction; Tamoxifen; Tegafur | 1999 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 1999 |
[Clinical study of selective intra-arterial infusion chemotherapy using trans-radial arterial approach in 4 cases of advanced breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Neoadjuvant Therapy; Radial Artery | 2000 |
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Medullary; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging | 1998 |
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Thiotepa; Treatment Outcome | 2000 |
[MR mammography of response-control in primary chemo-brachytherapy in BCT-inoperable breast cancer].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brachytherapy; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Contrast Media; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Gadolinium DTPA; Humans; Image Enhancement; Magnetic Resonance Imaging; Middle Aged; Preoperative Care; Time Factors | 2001 |
5-fluorouracil-induced leukoencephalopathy in patients with breast cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Brain; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Glucocorticoids; Humans; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Nervous System Diseases; Prednisolone; Radiography | 2001 |
[Results of treatment based on endocrine therapy for bone metastasis from breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone; Middle Aged; Palliative Care; Progesterone Congeners; Quality of Life; Survival Rate | 2001 |
Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Mastectomy, Radical; Medroxyprogesterone Acetate; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Drug Monitoring; Epirubicin; Female; Fluorouracil; Humans; Mammography; Mastectomy; Middle Aged; Mitoxantrone; Neoadjuvant Therapy; Paclitaxel; Physical Examination; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |